185 related articles for article (PubMed ID: 12781704)
1. Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor--BCX-1777.
Bantia S; Ananth SL; Parker CD; Horn LL; Upshaw R
Int Immunopharmacol; 2003 Jun; 3(6):879-87. PubMed ID: 12781704
[TBL] [Abstract][Full Text] [Related]
2. Potent orally bioavailable purine nucleoside phosphorylase inhibitor BCX-4208 induces apoptosis in B- and T-lymphocytes--a novel treatment approach for autoimmune diseases, organ transplantation and hematologic malignancies.
Bantia S; Parker C; Upshaw R; Cunningham A; Kotian P; Kilpatrick JM; Morris P; Chand P; Babu YS
Int Immunopharmacol; 2010 Jul; 10(7):784-90. PubMed ID: 20399911
[TBL] [Abstract][Full Text] [Related]
3. Comparison of in vivo efficacy of BCX-1777 and cyclosporin in xenogeneic graft-vs.-host disease: the role of dGTP in antiproliferative action of BCX-1777.
Banti S; Miller PJ; Parker CD; Ananth SL; Horn LL; Babu YS; Sandhu JS
Int Immunopharmacol; 2002 Jun; 2(7):913-23. PubMed ID: 12188033
[TBL] [Abstract][Full Text] [Related]
4. Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)--a novel potent and orally active immunosuppressive agent.
Bantia S; Miller PJ; Parker CD; Ananth SL; Horn LL; Kilpatrick JM; Morris PE; Hutchison TL; Montgomery JA; Sandhu JS
Int Immunopharmacol; 2001 Jun; 1(6):1199-210. PubMed ID: 11407314
[TBL] [Abstract][Full Text] [Related]
5. Purine nucleoside phosphorylase inhibitors in T-cell malignancies.
Bantia S; Kilpatrick JM
Curr Opin Drug Discov Devel; 2004 Mar; 7(2):243-7. PubMed ID: 15603259
[TBL] [Abstract][Full Text] [Related]
6. Functional and mechanistic studies on the toxicity of deoxyguanosine for the in vitro proliferation and differentiation of human peripheral blood B lymphocytes.
Scharenberg JG; Spaapen LJ; Rijkers GT; Duran M; Staal GE; Zegers BJ
Eur J Immunol; 1986 Apr; 16(4):381-7. PubMed ID: 3084280
[TBL] [Abstract][Full Text] [Related]
7. Effect of 9-benzyl-9-deazaguanine, a potent inhibitor of purine nucleoside phosphorylase, on the cytotoxicity and metabolism of 6-thio-2'-deoxyguanosine.
Parker WB; Allan PW; Niwas S; Montgomery JA; Bennett LL
Cancer Res; 1994 Apr; 54(7):1742-5. PubMed ID: 8137289
[TBL] [Abstract][Full Text] [Related]
8. A nelarabine-resistant T-lymphoblastic leukemia CCRF-CEM variant cell line is cross-resistant to the purine nucleoside phosphorylase inhibitor forodesine.
Yamauchi T; Uzui K; Nishi R; Tasaki T; Ueda T
Anticancer Res; 2014 Sep; 34(9):4885-92. PubMed ID: 25202070
[TBL] [Abstract][Full Text] [Related]
9. Forodesine (BCX-1777, Immucillin H)--a new purine nucleoside analogue: mechanism of action and potential clinical application.
Korycka A; Błoński JZ; Robak T
Mini Rev Med Chem; 2007 Sep; 7(9):976-83. PubMed ID: 17897085
[TBL] [Abstract][Full Text] [Related]
10. Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells.
Balakrishnan K; Nimmanapalli R; Ravandi F; Keating MJ; Gandhi V
Blood; 2006 Oct; 108(7):2392-8. PubMed ID: 16778146
[TBL] [Abstract][Full Text] [Related]
11. Intravenous and oral pharmacokinetic study of BCX-1777, a novel purine nucleoside phosphorylase transition-state inhibitor. In vivo effects on blood 2'-deoxyguanosine in primates.
Kilpatrick JM; Morris PE; Serota DG; Phillips D; Moore DR; Bennett JC; Babu YS
Int Immunopharmacol; 2003 Apr; 3(4):541-8. PubMed ID: 12689658
[TBL] [Abstract][Full Text] [Related]
12. Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes.
Kicska GA; Long L; Hörig H; Fairchild C; Tyler PC; Furneaux RH; Schramm VL; Kaufman HL
Proc Natl Acad Sci U S A; 2001 Apr; 98(8):4593-8. PubMed ID: 11287638
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of deoxyguanosine lymphotoxicity. Human thymocytes, but not peripheral blood lymphocytes accumulate deoxy-GTP in conditions simulating purine nucleoside phosphorylase deficiency.
Fairbanks LD; Taddeo A; Duley JA; Simmonds HA
J Immunol; 1990 Jan; 144(2):485-91. PubMed ID: 2104895
[TBL] [Abstract][Full Text] [Related]
14. A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine).
Gandhi V; Kilpatrick JM; Plunkett W; Ayres M; Harman L; Du M; Bantia S; Davisson J; Wierda WG; Faderl S; Kantarjian H; Thomas D
Blood; 2005 Dec; 106(13):4253-60. PubMed ID: 16131572
[TBL] [Abstract][Full Text] [Related]
15. Novel purine nucleoside analogues for T-cell-lineage acute lymphoblastic leukaemia and lymphoma.
Ravandi F; Gandhi V
Expert Opin Investig Drugs; 2006 Dec; 15(12):1601-13. PubMed ID: 17107284
[TBL] [Abstract][Full Text] [Related]
16. Drug evaluation: forodesine - PNP inhibitor for the treatment of leukemia, lymphoma and solid tumor.
Galmarini CM
IDrugs; 2006 Oct; 9(10):712-22. PubMed ID: 17016779
[TBL] [Abstract][Full Text] [Related]
17. In vivo and in vitro pharmacologic activity of the purine nucleoside phosphorylase inhibitor BCX-34: the role of GTP and dGTP.
Bantia S; Montgomery JA; Johnson HG; Walsh GM
Immunopharmacology; 1996 Oct; 35(1):53-63. PubMed ID: 8913795
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of 2'-deoxyguanosine toxicity in mouse T-lymphoma cells with purine nucleoside phosphorylase deficiency and resistance to inhibition of ribonucleotide reductase by dGTP.
Duan DS; Nagashima T; Hoshino T; Waldman F; Pawlak K; Sadee W
Biochem J; 1990 Jun; 268(3):725-31. PubMed ID: 2114100
[TBL] [Abstract][Full Text] [Related]
19. Effect of nucleoside and nucleotide reverse transcriptase inhibitors of HIV on endogenous nucleotide pools.
Vela JE; Miller MD; Rhodes GR; Ray AS
Antivir Ther; 2008; 13(6):789-97. PubMed ID: 18839780
[TBL] [Abstract][Full Text] [Related]
20. Determinants of sensitivity of human T-cell leukemia CCRF-CEM cells to immucillin-H.
Huang M; Wang Y; Gu J; Yang J; Noel K; Mitchell BS; Schramm VL; Graves LM
Leuk Res; 2008 Aug; 32(8):1268-78. PubMed ID: 18279955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
